Different requirements for α-galactosylceramide and recombinant IL-12 antitumor activity in the treatment of C-26 colon carcinoma hepatic metastases

نویسندگان
چکیده

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Colon carcinoma metastases with extension to chest wall and pericardium

Management of locally advanced colon cancer metastases is challenging and operation carries an increased risk of morbidity and mortality. The knowledge of exact sites of involvement can aid the surgeon to make a decision regarding complete resection or palliative therapy. PET/CT scan is an advantage in this setting because metabolic alterations often precede the anatomic changes; moreover, it c...

متن کامل

Combination suicide and cytokine gene therapy for hepatic metastases of colon carcinoma: sustained antitumor immunity prolongs animal survival.

The effectiveness of combination therapy using a suicide gene and cytokine genes for the treatment of metastatic colon carcinoma in the mouse liver was investigated. Pre-established hepatic tumors treated with a recombinant adenoviral vector containing the herpes simplex virus thymidine kinase gene(tk) exhibited substantial regression, although all treated animals suffered from subsequent relap...

متن کامل

The surgical treatment of hepatic metastases in colorectal carcinoma.

BACKGROUND Colorectal carcinoma with hepatic metastases was long considered an incurable disease. Recent advances in surgical treatment have substantially improved the affected patients' prognosis. At first, surgery was only performed in patients whose hepatic tumor burden was small (<4 nodes, <5 cm). Currently, however, the main issue is the feasibility of curative resection of all metastases....

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: European Journal of Immunology

سال: 2001

ISSN: 0014-2980,1521-4141

DOI: 10.1002/1521-4141(2001010)31:10<3101::aid-immu3101>3.0.co;2-8